NCT01794364 - Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Healthy

Interventions

DRUG

PF-06291874

PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.

OTHER

placebo

Correspondingly, placebo doses will be administered as suspension.

Trial Locations (1)

Pfizer Investigational Site, New Haven